FDA rejects Sobi's gout drug over manufacturing concerns, leaving Amgen's Krystexxa unchallenged
Sobi's (SOBI) attempt to bring a rival to Amgen's (AMGN) blockbuster gout treatment Krystexxa to market has been delayed after the US Food and Drug Administration declined to approve the Swedish company's drug.
